ChromaCode, MedGenome to launch HDPCR tech in India and Middle East

ChromaCode, MedGenome to launch HDPCR tech in India and Middle East

Time Stamp: April 28, 2023 9:26 AM
Source Node: 2616989
<!--

-->
The HDPCR NSCLC assay is proposed as an alternative to NGS in cancer biomarker testing. Credit: fernando zhiminaicela from Pixabay.

ChromaCode has formed a partnership with MedGenome to launch its high-definition polymerase chain reaction (HDPCR) multiplexing technology in India and the Middle East regions.

HDPCR technology is designed to enable deep multiplexing for the assessment of actionable biomarkers in a single assay for various sample types.

Its applications span several fields including oncology, minimal residual disease, transplant and noninvasive prenatal testing.

Utilising ChromaCode’s cloud-based analysis platform, this technology streamlines workflows to support laboratories across the world to conduct testing in-house and achieve better results.

ChromaCode plans to offer a comprehensive non-small cell lung cancer (NSCLC) test as the first oncology assay accessible on the platform. The assay will provide the capability to detect more than 200 variants across actionable genes within a single multiplexed assay, delivering results in less than 24 hours.

The HDPCR NSCLC assay is positioned as a viable substitute for next-generation sequencing (NGS) in cancer biomarker testing because of its benefits such as simple workflow, high sensitivity, low sample input needs and quick turnaround time.

ChromaCode chief business officer Padma Sundar said: “We are thrilled to partner with MedGenome, a leading laboratory in India that delivers innovative and trailblazing solutions for genetic testing, genomics research and drug discovery.

“Our partnership aims to introduce HDPCR technology to India and the Middle East, beginning with a fast, actionable and cost-effective test for NSCLC to help MedGenome serve their patient population.”

The evaluation of the assay with very low sample inputs showed a 99% concordance with NGS.

Furthermore, the PCR-based technology has achieved coverage of more than 99% for actionable genes, surpassing previous methods.

<!-- GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] --
googletag.cmd.push(function() { googletag.display('div-gpt-ad-8581390-1'); });
!-- End AdSlot 3 -->

Time Stamp:

More from Medical Device Network